Effect of a Practice-Wide Anti-TNF Proactive Therapeut Outcomes in Pediatric Patients With Inflammatory Bow

Inflammatory Bowel Diseases

27, 482-492

DOI: 10.1093/ibd/izaa102

Citation Report

#	Article	IF	Citations
1	Biological Therapy in Pediatric Age. Pharmacological Research, 2020, 161, 105120.	11.6	24
2	Second Mexican Consensus on Biologic Therapy and Small-Molecule Inhibitors in Inflammatory Bowel Disease. Revista De Gastroenterología De México (English Edition), 2021, 86, 70-85.	0.8	0
3	Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal. Revista De Gastroenterología De México, 2021, 86, 70-85.	0.2	2
4	Predicting Therapeutic Response in Pediatric Ulcerative Colitis—A Journey Towards Precision Medicine. Frontiers in Pediatrics, 2021, 9, 634739.	2.4	13
5	Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease. Frontiers in Pediatrics, 2021, 9, 661536.	2.4	23
6	A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2021, 116, 2014.	5.8	201
7	Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics, 2021, 13, 1786.	7.5	7
8	Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease: Unmet Needs and Future Perspectives. The Lancet Gastroenterology and Hepatology, 2022, 7, 171-185.	29.4	169
9	Optimizing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Focus on Therapeutic Monoclonal Antibodies. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1423-1431.	4.8	7
10	Therapeutic Drug Monitoring in Inflammatory Bowel Disease: At the Right Time in the Right Place. World Journal of Gastroenterology, 2022, 28, 1380-1383.	5.9	1
11	Antibodies-to-Infliximab Accelerate Clearance While Dose Intensification Reverses Immunogenicity and Recaptures Clinical Response in Paediatric Crohn's Disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 593-603.	7.7	45
12	Therapeutic Drug Monitoring for Biological Medications in Inflammatory Bowel Disease. Saudi Journal of Gastroenterology, 2022, 28, 322-331.	2.3	5
13	Denials, Dilly-Dallying, and Despair: Navigating.... Journal of Pediatric Gastroenterology and Nutrition, 2022, 75, 418-422.	3.3	11
14	La monitorización proactiva de niveles de anti-TNF mejora el seguimiento de los pacientes pediátricos con enfermedad de Crohn. Anales De Pediatría, 2023, 98, 165-174.	0.8	2
15	A Critical Review of Adalimumab for the Treatment of Moderate-to-Severe Active Ulcerative Colitis in Children. Expert Review of Gastroenterology and Hepatology, 2022, 16, 1023-1028.	3.5	1
16	Early Infliximab Clearance Predicts Remission in Children With Crohn's Disease. Digestive Diseases and Sciences, 2023, 68, 1995-2005.	3.0	15
17	Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases. Therapeutic Drug Monitoring, 2023, 45, 579.	2.2	28
18	Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH Trial. American Journal of Gastroenterology, 2023, 118, 485.	5.8	7

#	Article	IF	Citations
19	Proactive Monitoring of Anti-TNF Agents Improves Follow-Up of Paediatric Patients With Crohn Disease. Anales De Pediatría (English Edition), 2023, 98, 165-174.	0.8	2
20	Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. , 2023, .		0
21	Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. , 2023, .		16
22	Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience. Journal of Investigative Dermatology, 2023, 143, 1708-1716.e4.	4.3	8
23	Precision Medicine in Inflammatory Bowel Disease: Individualizing the Use of Biologics and Small Molecule Therapies. World Journal of Gastroenterology, 2023, 29, 1395-1406.	5.9	0
24	Precision Medicine in Inflammatory Bowel Disease: Individualizing the Use of Biologics and Small Molecule Therapies. World Journal of Gastroenterology, 2023, 29, 1539-1550.	5.9	16
25	Recent Advances in the Optimization of Anti-TNF Treatment in Patients With Inflammatory Bowel Disease. Journal of Clinical Medicine, 2023, 12, 2452.	3.8	16
26	The Role of Therapeutic Drug Monitoring in Children. Gastroenterology Clinics of North America, 2023, 52, 549-563.	3.6	6
27	Racial Disparities in Pediatric Inflammatory Bowel Disease Care: Differences in Outcomes and Health Service Utilization Between Black and White Children. Journal of Pediatrics, 2023, 260, 113522.	3.2	8
28	Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease. Current Gastroenterology Reports, 2023, 25, 323-332.	4.9	14
29	The Perceived Waning of Biologics in Severe Asthma. Respiratory Medicine, 2023, 219, 107416.	3.5	6
30	Managing Pediatric Crohn's Disease: Recent Insights. Expert Review of Gastroenterology and Hepatology, 2023, 17, 949-958.	3.5	3
31	Anti-Infliximab Antibodies and Low Infliximab Levels Correlate With Drug Discontinuation in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2024, 78, 261-271.	3.3	8
32	Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics. Inflammatory Bowel Diseases, 2024, 30, 1678-1685.	5.5	9
33	Proactive Therapeutic Drug Monitoring and Vedolizumab Dose Optimization in Children With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2024, 78, 853-861.	3.3	10
34	Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Paediatric Crohn's Disease (REMODEL-CD): Study Protocol for a Multicentre, Open-Label, Pragmatic Clinical Trial in the USA. BMJ Open, 2024, 14, e077193.	2.7	11
35	Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement From the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2024, 46, 291.	2.2	26
36	Biomarkers Predicting the Effect of Anti-TNF Treatment in Paediatric and Adult Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2024, 79, 62-75.	3.3	7

#	Article	IF	Citations
37	Characterization of Biologic Discontinuation Among Pediatric Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2024, 22, 2075-2083.e1.	10.5	12
38	The Role of Proactive Therapeutic Drug Monitoring in Guiding Infliximab Therapeutic Optimization in Pediatric Patients With Crohn's Disease: A Retrospective Study. Pediatric Discovery, 2024, 2, e96.	0.8	0
39	Different Infliximab Induction Dosing Regimens Do Not Affect Remission Rates Up to 1 Year in Children With Crohn's Disease. Journal of Pediatric Gastroenterology and Nutrition, 2024, 79, 564-572.	3.3	2
40	Is Therapeutic Drug Monitoring a Dancing Partner for TNF-α Inhibitors in Real-World Practice? Answers From an Updated Systematic Review and Meta-Analysis. Expert Review of Clinical Pharmacology, 2024, 17, 1-14.	3.6	5
41	Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Recent Developments. Expert Review of Gastroenterology and Hepatology, 2024, 18, 575-586.	3.5	12
42	Considerations in Paediatric and Adolescent Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2024, 18, ii31-ii45.	8.8	49
43	Model-Informed Precision Dosing in Inflammatory Bowel Diseases. Trends in Pharmacological Sciences, 2025, 46, 9-19.	19.8	6
44	Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study. Pharmaceutics, 2024, 16, 1577.	7.5	4
45	Calling in Your Markers: Can Biomarkers Predict the Response to Anti-TNF Therapy in Pediatric Patients With Crohn's Disease?. Digestive Diseases and Sciences, 2025, 70, 888-889.	3.0	1
46	Clinical and Biochemical Factors Associated With Infliximab Pharmacokinetics in Paediatric Patients With Inflammatory Bowel Disease. Journal of Clinical Medicine, 2025, 14, 845.	3.8	6
47	Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities – A Workshop Report. AAPS Journal, 2025, 27, 62.	3.8	11
48	North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2025, 81, 1100-1117.	3.3	22
49	Incidence of Anti-Drug Antibody Development in Older Adults With Inflammatory Bowel Disease Treated With Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study. Inflammatory Bowel Diseases, 2025, 31, 3356-3362.	5.5	1
50	Immunogenicity of Adalimumab in Patients With Noninfectious Uveitis Based on Therapeutic Drug Monitoring. Journal of Translational Medicine, 2025, 23, 1232.	9.4	5
51	Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease: An Evidence-Based Multidisciplinary Guideline. Acta Pharmaceutica Sinica B, 2026, 16, 616-641.	13.7	4
52	Impact of Proactive Therapeutic Drug Monitoring on Infliximab Maintenance Therapy and Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Randomized Controlled Trial and Review of Literature. Gastro Hep Advances, 2026, 5, 100953.	2.4	0
53	Is Routine Monitoring of TNF-α Inhibitor Levels and Antibodies in Pediatric IBD Justified in the Era of Personalized Medicine. Journal of Clinical Medicine, 2026, 15, 4098.	3.8	0
54	Management of Pediatric Crohn's Disease: An ECCO-ESPGHAN Guideline Update. Journal of Crohn's and Colitis, 2026, .	8.8	2

#	Article	IF	Citations
55	Evaluation of Pharmacokinetic Metrics and Pharmacodynamic Biomarkers Associated With Endoscopic Healing in Pediatric Crohn's Disease Patients Treated With Anti-Tumor Necrosis Factor Biologics. Crohn's & Colitis 360, 2026, 8, otag088.	2.5	0
56	Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide. Journal of Inflammation Research, 2026, 19, 1-24.	4.6	0
57	Large-Scale Proteomics Identifies a Pretreatment Crohn's Disease Core Proteome and a Dynamic Signature for Anti-TNF Response. Inflammatory Bowel Diseases, 2026, .	5.5	0